サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1426186

チェックポイント阻害剤の世界市場レポート 2024

Checkpoint Inhibitors Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 250 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
チェックポイント阻害剤の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 250 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

チェックポイント阻害剤の市場規模は、今後数年間で急速に成長すると予想されます。 2028年には10.1%の年間複合成長率（CAGR）で556億4,000万米ドルに成長すると予想されます。予測期間における予想される成長は、いくつかの要因、特にチェックポイント阻害剤の適応症の拡大、バイオマーカーの継続的な発見、併用療法の進化、個別化医療への注目の高まり、適応症の継続的な拡大によって生じると予想されます。

2022年 1月に米国がん協会が強調したように、世界のがん症例の急増は、新たな診断とがん関連死亡の予測増加によって後押しされ、チェックポイント阻害剤市場を牽引する態勢が整っています。女性の乳がんは新規症例のかなりの割合を占めており、これらのチェックポイントを対象としたチェックポイント阻害剤の有効性はがん治療において極めて重要です。これらの阻害剤の市場は、世界中でがんの発生率が上昇していることに対応して急増すると予想されています。

チェックポイント阻害剤市場は、ヘルスケア費の増加に伴ってさらに拡大するとみられています。この支出には、医薬品開発から患者へのアクセスとサポートに至るまで、さまざまな活動が含まれます。特に、国家統計局は、医薬品と予防医療への投資の増加を反映して、2020年から2021年にかけて英国のヘルスケア支出が大幅に増加したと報告しました。このようなヘルスケア支出の増加は、チェックポイント阻害剤市場の成長の背後にある重要な推進力です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のチェックポイント阻害剤市場、薬剤別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • PD-1阻害剤
  • PD-L1阻害剤
  • CTLA-4
  • キメラ抗原受容体T細胞
  • その他の薬剤
  • 世界のチェックポイント阻害剤市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 肺がん
  • 腎がん
  • 血液がん
  • 膀胱がん
  • 黒色腫
  • その他の用途
  • 世界のチェックポイント阻害剤市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 地域および国の分析

  • 世界のチェックポイント阻害剤市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のチェックポイント阻害剤市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • チェックポイント阻害剤市場の競合情勢
  • チェックポイント阻害剤市場の企業プロファイル
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • Merck &Co. Inc.
    • Roche Holding AG
    • Pfizer Inc

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

目次
Product Code: r13208

Checkpoint inhibitors represent a form of immunotherapy that disrupts the interaction between immune checkpoint proteins, enabling T cells to combat cancer cells by avoiding the suppression signal. Among these medications, one targets the checkpoint protein CTLA-4.

Within the realm of checkpoint inhibitors, the primary drug categories include PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, chimeric antigen receptor T-cells (CAR-T), and other variants. PD-1 and PD-L1 inhibitors specifically hinder the function of immune checkpoint proteins present on cell surfaces, aiding in the treatment of conditions like lung cancer, renal cancer, blood cancer, bladder cancer, melanoma, and more. These therapies find application across diverse sectors encompassing hospital pharmacies, retail pharmacies, and online pharmacy services.

The checkpoint inhibitors market research report is one of a series of new reports from The Business Research Company that provides checkpoint inhibitors market statistics, including checkpoint inhibitors industry global market size, regional shares, competitors with a checkpoint inhibitors market share, detailed checkpoint inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the checkpoint inhibitors industry. This checkpoint inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The checkpoint inhibitors market size has grown rapidly in recent years. It will grow from $32.41 billion in 2023 to $37.88 billion in 2024 at a compound annual growth rate (CAGR) of 16.9%. The growth observed in the historical period can be attributed to several factors, including the escalating incidence of cancer cases, heightened awareness surrounding checkpoint inhibitors, the broadening spectrum of approved checkpoint inhibitors, active research and development endeavors focused on novel checkpoint inhibitors, and the proliferation of clinical trials and extensive research in this field.

The checkpoint inhibitors market size is expected to see rapidly grown in the next few years. It will grow to $55.64 billion in 2028 at a compound annual growth rate (CAGR) of 10.1%. Anticipated growth in the forecast period is expected to stem from several factors, notably the expansion of indications for checkpoint inhibitors, ongoing discoveries in biomarkers, the evolution of combination therapies, the increasing focus on personalized medicine, and the continued broadening of indications.

The surge in global cancer cases is poised to drive the checkpoint inhibitors market, buoyed by a projected increase in new diagnoses and cancer-related deaths, as highlighted by the American Cancer Society in January 2022. With prevalent cancers like lung, prostate, bowel, and female breast cancer constituting a significant percentage of new cases, the efficacy of checkpoint inhibitors targeting these checkpoints stands pivotal in cancer therapy. The market for these inhibitors is expected to surge in response to the escalating rates of cancer incidence worldwide.

The checkpoint inhibitors market is set to expand further, propelled by a concurrent rise in healthcare expenditure. This expenditure encompasses a spectrum of activities, from drug development to patient access and support. Notably, the Office for National Statistics reported a substantial increase in healthcare spending in the UK between 2020 and 2021, reflecting a heightened investment in pharmaceuticals and preventive care. Such augmented healthcare expenditure is a key driver behind the growth of the checkpoint inhibitors market.

Major players in the checkpoint inhibitor realm are forging strategic partnerships to advance technologies like bifunctional fusion proteins or Y-trap, aiming to enhance the efficacy of immunotherapies. In June 2021, Merck and GSK's global strategic partnership to develop and market M7824 (bintrafusp alfa), an investigational bi-functional fusion protein immunotherapy, exemplifies this trend. Similarly, collaborations like GSK's alliance with ITeos Therapeutics seek to leverage expertise in immuno-oncology to expedite the development and commercialization of innovative therapies such as EOS-448.

Keytruda (pembrolizumab), an immunotherapy drug categorized as a checkpoint inhibitor, exemplifies the innovation in the checkpoint inhibitors market. Merck & Co., Inc. obtained FDA approval in March 2022 for Keytruda to treat patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial carcinoma. Keytruda's mechanism involves enabling the immune system to identify and combat cancer cells by blocking checkpoint proteins, offering an effective treatment avenue either individually or in combination with other cancer therapies.

In November 2021, Pfizer Inc., a US-based pharmaceutical industry company, acquired Trillium Therapeutics Inc. for $2.22 billion. Through this acquisition, Pfizer aims to strengthen its oncology portfolio with the addition of next-generation investigational immunotherapeutics for hematological malignancies and gain access to Trillium's two lead molecules. Trillium Therapeutics Inc. is a US-based biotech company developing innovative checkpoint inhibitors for the treatment of cancer.

Major companies operating in the checkpoint inhibitors market include AstraZeneca PLC, Bristol-Myers Squibb Company, Merck & Co. Inc., Roche Holding AG, Pfizer Inc., Incyte Corporation, Novartis AG, NewLink Genetics Corporation, Seattle Genetics Inc., Celldex Therapeutics, GlaxoSmithKline PLC, Innate Pharma S.A., Ono Pharmaceutical Co. Ltd., Juno Therapeutics, Kite Pharma, Eli Lilly and Company (ARMO Biosciences.), Fortress Biotech, Argenx SE, MacroGenics, CureTech, Sorrento Therapeutics, Sanofi S.A, F. Hoffmann-La Roche Ltd., AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Celgene Corporation, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Kyowa Kirin Co. Ltd., Johnson & Johnson, Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Y-mAbs Therapeutics Inc., Zai Lab Limited

North America was the largest region in the checkpoint inhibitors market in 2023. The Middle East is expected to be the fastest growing region in the global checkpoint inhibitors market share during the forecast period. The regions covered in the checkpoint inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the checkpoint inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The checkpoint inhibitors market consists of sales of atezolizumab, avelumab, and durvalumab. Values in this market are 'factory gate values,' that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Checkpoint Inhibitors Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on checkpoint inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for checkpoint inhibitors? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The checkpoint inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drug: PD-1 Inhibitors; PD-L1 Inhibitors; CTLA-4; Chimeric Antigen Receptor T-cell; Other Drugs
  • 2) By Application: Lung Cancer; Renal Cancer; Blood Cancer; Bladder Cancer; Melanoma; Other Applications
  • 3) By End-Users: Hospitals Pharmacies; Retail Pharmacies; Online Pharmacies
  • Companies Mentioned: AstraZeneca plc; Bristol-Myers Squibb Company; Merck & Co. Inc.; Roche Holding AG; Pfizer Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Checkpoint Inhibitors Market Characteristics

3. Checkpoint Inhibitors Market Trends And Strategies

4. Checkpoint Inhibitors Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Checkpoint Inhibitors Market Size and Growth

  • 5.1. Global Checkpoint Inhibitors Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Checkpoint Inhibitors Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Checkpoint Inhibitors Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Checkpoint Inhibitors Market Segmentation

  • 6.1. Global Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • PD-1 Inhibitors
  • PD-L1 Inhibitors
  • CTLA-4
  • Chimeric Antigen Receptor T-cell
  • Other Drugs
  • 6.2. Global Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Lung Cancer
  • Renal Cancer
  • Blood Cancer
  • Bladder Cancer
  • Melanoma
  • Other Applications
  • 6.3. Global Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

7. Checkpoint Inhibitors Market Regional And Country Analysis

  • 7.1. Global Checkpoint Inhibitors Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Checkpoint Inhibitors Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Checkpoint Inhibitors Market

  • 8.1. Asia-Pacific Checkpoint Inhibitors Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Checkpoint Inhibitors Market

  • 9.1. China Checkpoint Inhibitors Market Overview
  • 9.2. China Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Checkpoint Inhibitors Market

  • 10.1. India Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Checkpoint Inhibitors Market

  • 11.1. Japan Checkpoint Inhibitors Market Overview
  • 11.2. Japan Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Checkpoint Inhibitors Market

  • 12.1. Australia Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Checkpoint Inhibitors Market

  • 13.1. Indonesia Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Checkpoint Inhibitors Market

  • 14.1. South Korea Checkpoint Inhibitors Market Overview
  • 14.2. South Korea Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Checkpoint Inhibitors Market

  • 15.1. Western Europe Checkpoint Inhibitors Market Overview
  • 15.2. Western Europe Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Checkpoint Inhibitors Market

  • 16.1. UK Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Checkpoint Inhibitors Market

  • 17.1. Germany Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Checkpoint Inhibitors Market

  • 18.1. France Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Checkpoint Inhibitors Market

  • 19.1. Italy Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Checkpoint Inhibitors Market

  • 20.1. Spain Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Checkpoint Inhibitors Market

  • 21.1. Eastern Europe Checkpoint Inhibitors Market Overview
  • 21.2. Eastern Europe Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Checkpoint Inhibitors Market

  • 22.1. Russia Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Checkpoint Inhibitors Market

  • 23.1. North America Checkpoint Inhibitors Market Overview
  • 23.2. North America Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Checkpoint Inhibitors Market

  • 24.1. USA Checkpoint Inhibitors Market Overview
  • 24.2. USA Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Checkpoint Inhibitors Market

  • 25.1. Canada Checkpoint Inhibitors Market Overview
  • 25.2. Canada Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Checkpoint Inhibitors Market

  • 26.1. South America Checkpoint Inhibitors Market Overview
  • 26.2. South America Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Checkpoint Inhibitors Market

  • 27.1. Brazil Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Checkpoint Inhibitors Market

  • 28.1. Middle East Checkpoint Inhibitors Market Overview
  • 28.2. Middle East Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Checkpoint Inhibitors Market

  • 29.1. Africa Checkpoint Inhibitors Market Overview
  • 29.2. Africa Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Checkpoint Inhibitors Market Competitive Landscape And Company Profiles

  • 30.1. Checkpoint Inhibitors Market Competitive Landscape
  • 30.2. Checkpoint Inhibitors Market Company Profiles
    • 30.2.1. AstraZeneca plc
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Bristol-Myers Squibb Company
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co. Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Roche Holding AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Pfizer Inc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Checkpoint Inhibitors Market Competitive Benchmarking

32. Global Checkpoint Inhibitors Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Checkpoint Inhibitors Market

34. Checkpoint Inhibitors Market Future Outlook and Potential Analysis

  • 34.1 Checkpoint Inhibitors Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Checkpoint Inhibitors Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Checkpoint Inhibitors Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer